Tucatinib: 13 agencies, 2021–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 5.2 years, from 13 May 2021 at AWMSG (Wales) to 2026 at PBAC (Australia).
PBAC (Australia) changed its position: not recommended in 2021, recommended by 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 6 of 19 records date from 2023 or later.
4 distinct indication wordings are recorded for tucatinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 19 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess tucatinib, on 13 May 2021; DMC (Denmark) did not open a file until 3 Sep 2025 — a wide spread of 4.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 19 dated records fall in 2022 alone.
2 of the 13 agencies here assessed tucatinib more than once, CIPM (Spain) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
tucatinib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for tucatinib reads 11 recommended, 5 not recommended, 1 advice and 1 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| DMC (Denmark) | 3 Sep 2025 | Metastatisk HER2-positiv brystkræft - patienter, der har modtaget minimum to tidligere behandlinger | Anbefalet | source |
| CIPM (Spain) | 13 Apr 2023 | Indicación terapéutica autorizada: TUKYSA está indicado en combinación con trastuzumab y capecitabina para el tratamient… | financed by the SNS · art. 92 a, c | source |
| AOTMIT (Poland) | 31 Mar 2023 | programu lekowego „Leczenie chorych na raka piersi (ICD -10 C50) | recommended conditionally | source |
| AIFA (Italy) | 16 Nov 2022 | TUKYSA è indicato in associazione a trastuzumab e capecitabina per il trattamento di pazienti adulti affetti da cancro d… | innovative, since expired | source |
| PBAC (Australia) | 2021 | Breast cancer | Not recommended | source |
14 further decisions for tucatinib, across 10 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 19 decisions for tucatinib from 13 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.